FDA and EU Extend QbD Pilot Program and Continue to Clarify Expectations for QbD
This article was originally published in The Gold Sheet
Executive Summary
FDA and EU regulators have announced a two-year extension of the QbD joint review pilot program and are continuing to harmonize their approaches to QbD in a series of recent guides. In one change regulators said that they will no longer accept the use of the term “key process parameter” in assessing criticality because of the misuse of the term.
You may also be interested in...
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.
US FDA Mulls Advance Notice On Domestic Surveillance Inspections Post-COVID
Criticized for giving foreign sites advance notice of inspections, agency is considering giving such notice to domestic sites too even after surprise inspections become possible.